X4 Pharmaceuticals Profit Margin

The latest profit margin for XFOR is -568.8% as of June 2026. That compares with -311.15% in the prior-year period — down 82.8% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside X4 Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, XFOR's profit margin moved from -311.15% to -568.8% — a 82.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in X4 Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, XFOR currently prints -568.8% for profit margin, while the sector average sits near 13.89%. That is roughly 4194.1% below the sector mean. Large gaps often invite a closer look at X4 Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively X4 Pharmaceuticals converts resources into returns. At -568.8%, XFOR may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -311.15% in the prior-year period — down 82.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting XFOR's profit margin (-568.8%), review year-over-year change from -311.15%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.